Novel therapeutic agents for the treatment of early T-cell progenitor leukemia Ghent University
T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of pediatric and 25% of adult ALL cases and was originally identified as a highly aggressive tumor associated with poor prognosis. Recent studies have identified a subset of T-ALLs whose transcriptional programs resemble those of immature early T-cell progenitors (ETP) and hematopoietic stem cells. Importantly, these so-called ETP-ALLs have strong clinical relevance since they are ...